Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -2 of 2
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/1/2002
 
First Published:
4/1/1998
1.
Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18-79
NCI
UVACC-HIC-7621
UVA-HIC-7621, NCI-G98-1389, NCT00003222
Last Modified:
5/1/2000
 
First Published:
4/1/1998
2.
Phase I Study of Peptide 946 Melanoma Vaccine (Peptide 946), Peptide 946 Combined with Tetanus Peptide Melanoma Vaccine, or Peptide 946-Tetanus Peptide Conjugate in Patients with High Risk Melanoma (Summary Last Modified 05/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 to 79
NCI
UVACC-HIC-6346
UVA-HIC-6346, NCI-H98-0010, NCT00003224
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute